Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WG103
- Development stage
- Unknown
- Lead developer
- Wingor Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
WG103 is an investigational stem cell therapy being developed by **Shenzhen Wingor Biotechnology**. It is part of the company's 'WG' series of stem cell-based drug candidates, which are designed to treat a broad range of conditions including immune-mediated, chronic, and degenerative diseases. As of the latest pipeline reports, WG103 has reached the clinical filing stage, with its Investigational New Drug (IND) application having been accepted by the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE). The therapy likely leverages the natural regenerative and immunomodulatory properties of stem cells to address unmet medical needs in its target indications.
Beyond the preview
Go deeper on WG103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WG103.